Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMO-2055
- Development stage
- Discontinued
- Lead developer
- Aceragen
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
IMO-2055 is a synthetic immunomodulatory oligonucleotide and a Toll-like receptor 9 (TLR9) agonist. It mimics unmethylated CpG sequences found in bacterial DNA to stimulate the innate immune system via TLR9 activation. This immune stimulation is intended to enhance antitumor responses and potentiate the efficacy of other anticancer agents. Developed primarily as an anticancer agent for solid tumors such as colorectal cancer, non-small cell lung cancer (NSCLC), head and neck cancer, and renal cell carcinoma, it was investigated in combination with various chemotherapeutic and targeted therapies. Despite promising early-phase results showing immune activation and some disease control in NSCLC trials when combined with agents like Tarceva (erlotinib) and Avastin (bevacizumab), later-stage studies failed to meet primary endpoints for progression-free survival in several cancers. Development has been discontinued or suspended for all major indications[2][4][6][7][8].
- Brand names
- IMOxine
- Other names
- TLR9 agonist IMO-2055TLR-9 agonist IMO-2055TLR 9 agonist IMO-2055EMD 1201081EMD1201081EMD-1201081HYB-2055HYB2055HYB 2055
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on IMO-2055.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMO-2055.